In today's fast growing inhalables market, the availability of suitable, efficient and cost-effective means of gathering particle analysis data for pulmonary formulation is clear. At this year's Drug Delivery to the Lungs 20 (DDL 20) meeting, experts from ChemImage Corporation, will be on hand to discuss our patented chemical imaging technology and how ingredient-specific particle sizing (ISPS) fulfils precisely this requirement for drug particle size data.
Obtaining drug particle size information in respiratory products is important to understand the deliverable drug load, respirable fraction, and overall quality as well as from a cost perspective. Prior to entering clinical trials, this additional data can provide invaluable information, raising confidence and lowering risk of failure in vivo biostudies. The value and importance of gaining this information before taking the expensive step of beginning clinical development cannot be emphasized enough.
"We are excited to be able to provide our customers with information that can both improve the quality of their respiratory products as well as save them time and money in the long run," said Dr. Thomas Voigt, Executive Vice President of ChemImage Corporation.